SCHEMBL1894591

SCHEMBL1894591

O=C1c2ccccc2C(=O)N1CCCC#Cc1cccc(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.50
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1B1 Q16678 2/20 0.43
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC8 Q9BY41 3/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892469 0.84 MAPT (0.47) RAB9AMAPTSMN1; SMN2TDP1L3MBTL1
SCHEMBL30006541 0.83 RAB9A (0.48) RAB9ASMN1; SMN2CYP1B1ALDH1A1
SCHEMBL2754682 0.76 CYP1B1 (0.61) RAB9ACYP1B1ALDH1A1TDP1L3MBTL1
SCHEMBL6122839 0.75 RAB9A (0.50) RAB9AMAPTSMN1; SMN2TDP1L3MBTL1
SCHEMBL11758524 0.75 TDP1 (0.53) RAB9AMAPTSMN1; SMN2TDP1L3MBTL1
SCHEMBL12709318 0.73 GSK3B (0.45) RAB9AMAPTSMN1; SMN2HDAC8HDAC3
SCHEMBL31626928 0.73 RAB9A (0.46) RAB9AMAPTSMN1; SMN2CYP1B1ALDH1A1
SCHEMBL12709324 0.73 ALDH1A1 (0.45) RAB9AMAPTSMN1; SMN2ALDH1A1HDAC8
SCHEMBL4351612 0.72 TDP1 (0.66) RAB9AMAPTSMN1; SMN2TDP1L3MBTL1
SCHEMBL16030725 0.72 TDP1 (0.68) RAB9ACYP1B1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2493571-B1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2014-07-23 EP disclosed
US-8633322-B2 Alkynyl derivatives useful as DPP-1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-01-21 US disclosed
EP-2493571-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP disclosed
WO-2011059731-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-05-19 WO disclosed
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105562-A1 ALKYNYL DERIVATIVES USEFUL AS DPP-1 INHIBITORS DPP4, DPP3, DPP7 RAB9A 2507/4885MAPT 2030/4885SMN1; SMN2 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.